Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totalling 505,200 shares, an increase of 8.3% from the August 31st total of 466,600 shares. Based on an average daily trading volume, of 46,500 shares, the short-interest ratio is currently 10.9 days. Approximately 8.5% of the company’s stock are sold short.

Greenwich LifeSciences Stock Down 3.5 %

GLSI traded down $0.51 during trading on Tuesday, hitting $13.86. The company’s stock had a trading volume of 31,334 shares, compared to its average volume of 42,640. Greenwich LifeSciences has a one year low of $7.58 and a one year high of $21.44. The business’s 50 day simple moving average is $14.44 and its 200-day simple moving average is $15.05. The firm has a market cap of $178.52 million, a PE ratio of -19.69 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last released its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.20). Equities research analysts expect that Greenwich LifeSciences will post -0.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lifted their price objective on Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Friday, August 23rd.

Insider Transactions at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 5,500 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was bought at an average cost of $13.18 per share, with a total value of $72,490.00. Following the transaction, the chief executive officer now directly owns 5,532,602 shares in the company, valued at approximately $72,919,694.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired 11,300 shares of company stock valued at $160,500 in the last three months. 52.86% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

Several institutional investors have recently modified their holdings of GLSI. Rhumbline Advisers bought a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth about $117,000. Bank of New York Mellon Corp bought a new position in shares of Greenwich LifeSciences during the second quarter valued at approximately $264,000. Finally, Vanguard Group Inc. grew its stake in shares of Greenwich LifeSciences by 0.6% during the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after buying an additional 1,420 shares during the last quarter. 4.16% of the stock is owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.